The firm has discussed positive Phase I results on BCB-276 with the FDA and plans to move it directly to a registrational trial by year-end.

Chinese regulators approved the drug for the same subset of advanced, previously treated EGFR-mutated NSCLC patients in 2023.

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.